This Sempra Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Monday - Sempra (NYSE:SRE), PG&E
Analysts downgraded Sempra (SRE) from Outperform to Neutral, cutting its price target from $104 to $84. PG&E (PCG) was downgraded from Outperform to Market Perform with a target reduced from $28 to $21. Edison International (EIX) was also downgraded to Neutral with a target lowered from $86 to $70. MINISO Group (MNSO) was downgraded to Hold with a $10.8 target. Tenax Therapeutics (TENX) was downgraded to Neutral.
How this was made
The 30-second read
Why it matters
For each named issuer, the immediate tradable signal is the downgrade direction and any target reduction, which can influence positioning and short-term sentiment even without new company disclosures.
Market read
This is a multi-name analyst-action roundup. The most actionable element is the direction and magnitude of target cuts for SRE and PCG, which can drive Monday positioning.
What to watch
The article does not include the downgrade rationale, so traders may overreact to the rating change without knowing whether it reflects valuation, near-term estimates, or longer-term fundamentals.
Background
Benzinga summarizes analyst rating changes for several stocks, highlighting downgrades and (where provided) reduced price targets.
Ticker impact
Mizuho downgraded Sempra from Outperform to Neutral and cut its price target from $104 to $84.
Near-term downside bias; expect volatility around analyst-reaction flows rather than a fundamental re-rate.
The article provides a clear rating change and target cut, but no new company-specific operational or financial datapoint beyond the analyst action.
BMO downgraded PG&E from Outperform to Market Perform and reduced the price target from $28 to $21.
Moderate downside bias, with potential for continued selling if other analysts follow.
The downgrade is explicit and includes a sizable target reduction, but the article does not include the underlying thesis or new PG&E disclosures.
Mizuho downgraded Edison International from Outperform to Neutral and lowered the price target from $86 to $70.
Short-term negative drift risk, especially if the market treats the move as sector read-across.
The article lists the downgrade and target cut but provides no rationale or incremental facts to gauge magnitude versus already-known concerns.
HSBC downgraded MINISO Group Holding from Buy to Hold and set a $10.8 price target.
Mild-to-moderate downside bias, depending on how investors interpret the target versus current price.
No thesis or new MINISO-specific catalyst is included, limiting conviction on follow-through.
Guggenheim downgraded Tenax Therapeutics from Buy to Neutral.
Potential near-term weakness, but likely limited without a target change or new trial/regulatory data.
The article provides only the rating change, with no price target or new clinical/regulatory information.
Market effects
Multiple downgrades across utilities and related names suggest a risk-off tilt in rate/regulatory and earnings-quality expectations, at least from these analysts.
Primarily US-listed equities, with potential spillover into broader US utility and power-adjacent sentiment.
Limited; one China-listed consumer brand name is included, but no global macro catalyst is described.
Counterpoint
Analyst downgrades often lag fundamentals; if the market already priced in weaker outlooks, the incremental impact may fade quickly.
Key entities
- companySempra
Downgraded by Mizuho from Outperform to Neutral; price target cut to $84.
- companyPG&E Corporation
Downgraded by BMO from Outperform to Market Perform; price target cut to $21.
- companyEdison International
Downgraded by Mizuho from Outperform to Neutral; price target cut to $70.
- companyMINISO Group Holding Limited
Downgraded by HSBC from Buy to Hold; $10.8 price target.
- companyTenax Therapeutics, Inc.
Downgraded by Guggenheim from Buy to Neutral.
